UNSPSC 51102819: Betamethasone/clotrimazole

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE250. This VA Drug Class (DE250) classifies this compound as belonging to the group ANTI-INFECTIVE/ANTI-INFLAMMATORY COMBINATIONS, TOPICAL.

UNSPSC 51102819 Betamethasone/clotrimazole is a Commodity code for a specific pharmaceutical product, but the recent state and local contract opportunities posted under this code do not reflect purchases of betamethasone/clotrimazole itself. Instead, the opportunities show state and local governments procuring other pharmaceutical products and medical supplies — including antibiotic tablets, naloxone, and drug deactivation systems — through cooperative purchasing vehicles and competitive bidding. The issuing bodies include state health departments and county governments pursuing pharmaceutical warehouse supply contracts and community health initiatives.

Activity under this code appears sparse and geographically limited. The Illinois Department of Public Health awarded a completed piggyback pharmaceutical warehouse contract through the MMCAP Infuse cooperative to Chartwell Rx LLC on August 28, 2026, for Doxycycline Hyclate and Ciprofloxacin Hydrochloride tablets totaling $2,999,999.11 over the contract life, with an initial 12-month term and renewal options for years 2 and 3. Seminole County, Florida posted an IFB on June 30, 2026, for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the county community health building, though the response deadline stated in the record (July 26, 2023) appears misaligned with the post date. The code shows little recent relevant activity, and the opportunities currently tagged to it do not align with the betamethasone/clotrimazole scope that the code nominally describes.